Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is a worldwide public health concern for which no vaccine is available. Elucidation of the prefusion structure of the RSV F glycoprotein and its identification as the main target of neutralizing antibodies have provided new opportunities for development of an effective vaccine. Here, we describe the structure-based design of a self-assembling protein nanoparticle presenting a prefusion-stabilized variant of the F glycoprotein trimer (DS-Cav1) in a repetitive array on the nanoparticle exterior. The two-component nature of the nanoparticle scaffold enabled the production of highly ordered, monodisperse immunogens that display DS-Cav1 at controllable density. In mice and nonhuman…

• HH
  Howard Hughes Medical Institute
• BW
  Burroughs Wellcome Fund
• BA
  Bill and Melinda Gates Foundation

  Awards: OPP1126258, OPP1120319, OPP1162875
• EM
  European Molecular Biology Organization

  Award: ALTF 933-2015
• NO
  Nederlandse Organisatie voor Wetenschappelijk Onderzoek

  Awards: 019.2015.2.310.006, Rubicon 019.2015.2.310.006
• KI
  Karolinska Institutet
• V
  Vetenskapsrådet

  Award: 2015-02608
• NI
  National Institute of General Medical Sciences

  Award: R01GM120553
• NI
  National Institute of Allergy and Infectious Diseases

  Award: HHSN272201700059C